Illumina Inc
ILMN: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$363.00 | Qpqkncn | Mtksykng |
No Fair Value Estimate Change as Illumina Trims 2022 Outlook Again but Order Book Impresses
Narrow-moat genomic sequencing leader Illumina turned in third-quarter financial results that were slightly better than expected. However, given external challenges and its own new product pipeline cannibalizing sales, the firm trimmed its outlook for 2022. At first glance, we are maintaining our fair value estimate, and we think investors with a long-term horizon should view any share weakness as an opportunity.